We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Albemarle (ALB - Free Report) ended the recent trading session at $194.04, demonstrating a -1.35% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.29% for the day. On the other hand, the Dow registered a loss of 0.31%, and the technology-centric Nasdaq increased by 0.89%.
Shares of the specialty chemicals company witnessed a gain of 10.45% over the previous month, beating the performance of the Basic Materials sector with its gain of 1.95%, and underperforming the S&P 500's gain of 10.54%.
Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to go public on May 6, 2026. The company is expected to report EPS of $1.24, up 788.89% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $1.33 billion, reflecting a 23.05% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.72 per share and a revenue of $5.8 billion, signifying shifts of +1203.8% and +12.87%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Albemarle. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 7.01% higher. Albemarle presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Albemarle is presently trading at a Forward P/E ratio of 22.55. This represents a premium compared to its industry average Forward P/E of 19.63.
Investors should also note that ALB has a PEG ratio of 1.41 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Chemical - Diversified industry stood at 1.58 at the close of the market yesterday.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 152, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Stock Declines While Market Improves: Some Information for Investors
Albemarle (ALB - Free Report) ended the recent trading session at $194.04, demonstrating a -1.35% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.29% for the day. On the other hand, the Dow registered a loss of 0.31%, and the technology-centric Nasdaq increased by 0.89%.
Shares of the specialty chemicals company witnessed a gain of 10.45% over the previous month, beating the performance of the Basic Materials sector with its gain of 1.95%, and underperforming the S&P 500's gain of 10.54%.
Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to go public on May 6, 2026. The company is expected to report EPS of $1.24, up 788.89% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $1.33 billion, reflecting a 23.05% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.72 per share and a revenue of $5.8 billion, signifying shifts of +1203.8% and +12.87%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Albemarle. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 7.01% higher. Albemarle presently features a Zacks Rank of #3 (Hold).
Looking at valuation, Albemarle is presently trading at a Forward P/E ratio of 22.55. This represents a premium compared to its industry average Forward P/E of 19.63.
Investors should also note that ALB has a PEG ratio of 1.41 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Chemical - Diversified industry stood at 1.58 at the close of the market yesterday.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 152, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.